ScoreWhy is Xbrane Biopharma AB ?
1
With a fall in EPS of -119.11%, the company declared Very Negative results in Mar 26
- The company has declared negative results for the last 2 consecutive quarters
- NET PROFIT(HY) At SEK -38.98 MM has Grown at -610.13%
- NET SALES(Q) At SEK 17.34 MM has Fallen at -54.48%
- INVENTORY TURNOVER RATIO(HY) Lowest at 0.22 times
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -65.81%, its profits have risen by 74.7%
3
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -65.81% returns in the last 1 year, the stock has also underperformed OMX Stockholm 30 in each of the last 3 annual periods
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Xbrane Biopharma AB for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Xbrane Biopharma AB
-100.0%
0.36
9421.56%
OMX Stockholm 30
28.68%
1.80
15.95%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
173.61%
EBIT Growth (5y)
13.12%
EBIT to Interest (avg)
-67.28
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.58
Sales to Capital Employed (avg)
0.43
Tax Ratio
8.45%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.21
EV to EBIT
-2.84
EV to EBITDA
-5.35
EV to Capital Employed
0.17
EV to Sales
0.58
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-5.84%
ROE (Latest)
-8.23%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Bearish
Bearish
OBV
Bearish
Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend5What is working for the Company
NET PROFIT(HY)
Higher at SEK -38.98 MM
-24What is not working for the Company
NET PROFIT(HY)
At SEK -38.98 MM has Grown at -610.13%
NET SALES(Q)
At SEK 17.34 MM has Fallen at -54.48%
INVENTORY TURNOVER RATIO(HY)
Lowest at 0.22 times
INTEREST(Q)
At SEK 2.19 MM has Grown at 42.63%
RAW MATERIAL COST(Y)
Grown by 55.41% (YoY
Here's what is working for Xbrane Biopharma AB
Net Profit
Higher at SEK -38.98 MM
than preceding 12 month period ended Mar 2026MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (SEK MM)
Here's what is not working for Xbrane Biopharma AB
Net Profit
At SEK -38.98 MM has Grown at -610.13%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very negative
Net Profit (SEK MM)
Net Sales
At SEK 17.34 MM has Fallen at -54.48%
over average net sales of the previous four periods of SEK 38.09 MMMOJO Watch
Near term sales trend is extremely negative
Net Sales (SEK MM)
Interest
At SEK 2.19 MM has Grown at 42.63%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (SEK MM)
Inventory Turnover Ratio
Lowest at 0.22 times and Fallen
In each half year in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
Raw Material Cost
Grown by 55.41% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
